ATRC AtriCure Inc.

AtriCure Announces Hiring of Chief Technology Officer

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has hired Salvatore (Sam) Privitera as its Chief Technology Officer. Mr. Privitera will have responsibility for Research and Development activities, as well as Operations, including manufacturing, supply chain, and quality systems.

Most recently, Mr. Privitera served as Vice President of Research and Development at Bard Medical (“BMD”), a division of C.R. Bard (NYSE: BCR), where he helped grow BMD approximately 40% in 5 years to over $1 billion in revenue globally. He was responsible for a broad range of clinical platforms including Therapeutic Hypothermia, Urologic Drainage, Endourology, Brachytherapy, and Home Care where they impacted over 150 million patients on an annual basis. Additionally, he led multiple discrete design centers, while delivering products into seven global manufacturing centers and numerous supply partners. Prior to his role at Bard, he worked for AtriCure as the Vice President of Engineering and Product Development for ten years. During his tenure at AtriCure, the company grew from a small startup into a public company, and he led development of many platform technologies including the AtriClip product line and the PMA approved Isolator® Synergy™ Ablation System. Prior to AtriCure, Mr. Privitera worked at Ethicon Endo-Surgery, a Johnson and Johnson company, in a variety of research, development and operations roles.

“We are excited to have Sam joining us again at AtriCure,” said Mike Carrel, President and Chief Executive Officer. “He is well recognized as a creative, pragmatic and patient centric innovator with an eye towards bringing high quality products to market efficiently. Additionally, he obviously knows the company well, having served here previously, and he brings a wealth of experience in the Afib space and a deep understanding of the close link between product development and operations. Now is an excellent time to bring him on as we look to continue to scale our organization to support our growth objectives.”

“I am thrilled to be joining AtriCure at such an exciting time in the company’s evolution,” said Mr. Privitera. “The company has not only done a great job of bringing new technologies to market over the past several years, it has scaled operations without any compromise in the quality standards that have always been integral to its culture. With a broad portfolio of products, and an exciting pipeline, the company is well positioned to build on its leadership position in the treatment of persistent and long-standing persistent Afib.”

“Since the beginning of 2014, we have brought eight new products to market in the United States, inclusive of two acquisitions (Endoscopic Technologies, Inc d/b/a Estech, and nContact, Inc.),” continued Mr. Carrel. “These products have contributed meaningfully to our growth, and I’m proud of our teams for their efforts. Sam is joining a high performing team that has a proven track record.”

About AtriCure, Inc.

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter @AtriCure.

EN
18/07/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AtriCure Inc.

 PRESS RELEASE

AtriCure to Host Analyst & Investor Day on March 26, 2025

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expansion at our Analyst and Investor Day. We also look forward to bringing perspectives from key opinion leaders as well as sharing ...

 PRESS RELEASE

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Resu...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key franchises,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “With the breadth and performance of our busi...

 PRESS RELEASE

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Resul...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 financial results. Those interested in listening to the conference call should . Participants are encouraged to register more t...

 PRESS RELEASE

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year ...

MASON, Ohio--(BUSINESS WIRE)-- , a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced preliminary financial results for the fourth quarter and full year 2024 and provided 2025 financial guidance. Additionally, AtriCure announced that it will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025. Preliminary, unaudited revenue for fourth quarter 2024 is expected to be $124.3 million, reflecting growth of approximately 17% as r...

 PRESS RELEASE

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conf...

MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure’s management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at . About AtriCure AtriCure, I...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch